AI-powered Drug Discovery start-up Peptris raises $1M in pre-seed funding led by Speciale Invest

Peptris Technologies Private Limited, a Bangalore-based AI drug discovery company, has announced $1 million in pre-seed round investment led by Speciale Invest.

Peptris Technologies Private Limited, a Bangalore-based AI drug discovery company, has announced $1 million in pre-seed round investment led by Speciale Invest.

The funding would help boost the company’s efforts in advancing AI-driven solutions in the drug development/discovery sector, with a special focus on developing novel therapies for undruggable targets, particularly in oncology, inflammation, and rare diseases.

Peptris, through its AI platform, aims to transform the traditionally lengthy and costly drug discovery process, which often spans over a decade and incurs substantial costs, making essential medications financially out of reach for many.

The company’s technology narrows down extensive chemical libraries to pinpoint promising drug candidates, marking a significant advancement over traditional drug discovery methods.

The team at Peptris intends to leverage and capitalize on the recent maturation of AI technology in developing its proprietary drug discovery platform. The strides in unsupervised learning and the availability of vast chemical libraries have opened new avenues in the sector, offering substantial market opportunities.

Peptris is capitalizing on this opportunity by developing a proprietary AI platform that reduces preclinical development timelines and costs multifold.

The company is broadening its research scope to include rare diseases, in addition to its ongoing work in oncology and inflammation. This strategic expansion aligns with the company’s mission to leverage AI for the rapid and efficient discovery of novel therapeutic options. The integration of AI in drug discovery, particularly in the context of rare diseases, addresses over 7000 known conditions lacking approved treatments.